Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates
Curis shares positive updated clinical data for emavusertib and increases its year-end guidance for the TakeAim CLL study.
Curis reported that their cancer medicine is working better than expected in tests, so they feel more confident about their progress this year. When a medicine company shares good results like this, it can mean their business might grow—so watch if they keep delivering on these promises.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.